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Background: Human immunodeficiency virus (HIV) associated anemia is common and it is a challenge for
prognosis of HIV positive patients. It is stated in different literature that the prevalence of anemia due to HIV before
highly active antiretroviral therapy (HAART) initiation is more prevalent than after HAART initiation. Thus this study
aimed to assess anemia prevalence before and after initiation of HAART among HIV patients attending university of
Gondar hospital from 2008 – 2013.
Methods: A retrospective study was conducted by collecting data from antiretroviral clinic of University of Gondar
Hospital from January 1, 2008 to December 30, 2013. Data was collected by using data collection sheet which
contains age, sex, regimen type, hematological parameters and CD4 cell count. Data were analyzed using SPSS
version 20. In order to compare means paired t-test was used. P- Value <0.05 was considered as significant.
Results: Prevalence of anemia before and after HAART initiation was 21.2% and 11.5% respectively. There is a
significance difference in CD4 cell count, hemoglobin and hematocrit values on patients before and after HAART
initiation (P <0.001). Opportunistic infection and CD4 cell count were associated with prevalence of anemia before
HAART initiation.
Conclusion: There was a decline in the prevalence of anemia and increment of mean CD4 cell count among HIV
infected patients after HAART initiation. HIV patients are recommended checking up their CD4 cell counts regularly
and starting HAART when it is appropriate with regular follow-up.
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Anemia is the most common hematological abnormality
in HIV positive patients. It has been shown to be the
risk factor for early death in patients with AIDS. Anemia
is not only associated with decreased quality of life but it
is also independently associated with decreased survival
with HIV [1]. It is developed in close to 95% of HIV in-
fected patients before the initiation of HAART, and still
found in up to 46% of patients in the HAART [2,3].* Correspondence: bamlak21@gmail.com
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article, unless otherwise stated.Previous studies have found that the incidence of anemia
increases with progression of HIV infection. Several other
etiologic factors may also be involved in the development
of HIV-associated anemia, including micronutrient de-
ficiencies, immunological myelosuppression, impaired
erythropoietin production and blood loss from intes-
tinal opportunistic disease [4].
Anemia is a condition in which there is a decrease in
the red blood cell count, hemoglobin and/or hematocrit
values as compared to normal reference range for age,
sex, race and altitude which decreases oxygen-carrying
capacity of red blood cells to tissues [5]. It is defined as
a hemoglobin level <12 g/dl for adult female and <13 g/dl
for adult male, in accordance with WHO guidelines andd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Socio demographic and clinical characteristics of
HIV positive patients attending University of Gondar
hospital, North West Ethiopia from 2008-2013
Variables Frequency Percentage
Sex Male 131 37.5
Female 218 62.5
Age <25 years 46 13.2
26-35 years 154 44.1
36-45 years 114 32.7
>46 years 35 10.0
Regimen type AZT based 215 61.6
Non AZT based 134 38.4
Cotrimoxazole Yes 306 87.7
NO 43 12.3
Opportunistic
infections (OPIs)
Yes 15 4.3
No 334 95.7
WHO stage WHO stage I & II 226 64.8
WHO stage III & IV 123 35.2
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12.9 g/dl for men), moderate (8–10.9 g/dl) and severe
(<8 g/dl) [6].
Anemia is observed in both antiretroviral therapy treated
and untreated individuals, but severity varies due to the
immune status or CD4 cell levels and also the prevalence
increases as the disease advanced and left untreated [7].
If an individual used antiretroviral treatment effectively,
there will be an increased level of CD4 cells and
hemoglobin concentration, which in turn decrease the
occurrence of anemia [8-14]. Although HIV infected pa-
tients on HAART showed lower prevalence of anemia,
some reports indicated that AZT can induces anaemia [15].
Most studies described the prevalence of anemia in
HIV infected individuals before and after initiation of
highly active antiretroviral therapy (HAART), however
few studies were conducted in Ethiopia on the assess-
ment of anemia among HIV positive patients [11,12,16].
Therefore, this study gave information about the anemia
before and after initiation of antiretroviral therapy among
patients who attend at ART clinic of Gondar University
Hospital.
Methods
Study setting and study population
This retrospective study was conducted in the ART clinic
of the University of Gondar Hospital which is found in
Northwest of Ethiopia. Patients’ data with full information
of sex, age, regimen type, hematological and immuno-
logical parameters, WHO clinical stage, type of regimen,
opportunistic infections and cotrimoxazole were collected
from follow up charts and registration books of patients
who started HAART at GUH ART clinic from January 1,
2008 to December 30, 2013. Hematological and immuno-
logical parameters were collected at baseline when the
HIV positive patients adhere to ART and after six month
of HAART initiation. The quality of data were controlled
at different levels for completeness and consistency.
Whenever an error was found at any level, it was corrected
by rechecking from the registration book.
Statistical analysis
The data were cleaned, edited, checked for completeness
and entered into SPSS version 20 for analysis. Descriptive
statistics was used to get a clear picture of dependent and
independent variables. In order to compare means paired
t-test was used and also chi square was computed to deter-
mine association between dependent and independent var-
iables. P- Value <0.05 was considered as significant.
Ethical consideration
The study was conducted after ethical letters obtained
from School of Biomedical and Laboratory Science Ethical
Committee. Then permission was taken from hospitalhigher management. After permission was obtained, data
were collected from ART clinic. To keep confidentiality
codes were used and unauthorized person didn’t have ac-
cess to the data.
Results
General characteristics of study participants
A total of 349 HIV positive patients, 218 (62.5%) females
and 131 (37.5%) males, were involved in this study. The
overall mean age was 34.6 ± 8.5 years, within the range
of 15 – 60 years old. Majority of the patients [154
(44.1%)] were within 26 – 35 years of age. About 226
(64.8%) of participants were under WHO clinical stage I
& II, 87.7% of them were taking cotrimoxazole prophy-
laxis therapy and about 4.3% of them were TB co-
infected (Table 1).
Laboratory profile of HIV positive patients
The mean WBC count, hemoglobin, platelet and CD4 cell
count before HAART initiation were 5.62 ± 2.13 cells/μl,
13.65 ± 2.14 g/dl, 279.33 ± 101 cells/μl and 251.72 ± 164.15
cells/μl and after HAART initiation were 5.58 ± 2 cells/μl,
14.04 ± 1.75 g/dl, 289.15 ± 99.43cells/μl and 295.85 ± 155
cells/μl respectively. Patients after HAART initiation have
high hemoglobin level, hematocrit and CD4 cell count
when compared to before HAART initiation patients
(P <0.001) (Table 2).
Prevalence of anemia among HIV positive patients
The prevalence of anemia in HIV patients was 21.2%
(74/114) before HAART initiation and 11.5% (40/114)
after HAART initiation. About 40 (11.5%) had mild
Table 2 Hematological parameters of HIV positive
patients before and after initiation of HAART at
University of Gondar Hospital Northwest Ethiopia from
2008 – 2013
Parameters Before HAART
initiation
After HAART
initiation
95% CI P –
Value
Mean ± SD Mean ± SD
WBC 5.62 ± 2.13 5.58 ± 2 −0.175 – 0.253 0.722
Lymphocyte 1.95 ± 1 1.93 ± 0.86 −0.101 – 0.127 0.822
Mixed 0.63 ± 0.33 0.6 ± 0.27 −0.05 – 0.062 0.096
Granulocyte 3.04 ± 1.61 3.05 ± 1.45 −0.159 – 0.151 0.958
Hemoglobin 13.65 ± 2.14 14.04 ± 1.75 −0.174 – (−)3.55 0.000*
Hematocrit 40.4 ± 6.34 42.15 ± 5.67 −1.05 – (−) 4.88 0.000*
Platelet 279.33 ± 101 289.15 ± 99.43 −20.789 – 1.156 0.079
CD4 cells//μl 251.72 ± 164.15 295.85 ± 155 −30.61 – (−)6.42 0.000*
Note: Level of significance (P Value) is determined based on paired sample
T test.
Numbers with atrix (*) indicates significance.
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severe anemia before HAART initiation. However, the
prevalence of anemia after HAART initiation was signifi-
cantly decreased by 9.7% (Figure 1).
Risk factors of anemia in HIV infected patients
From anemic patients before HAART initiation, about
19.8% (26/131) were males and 22% (48/118) were females.
Similarly 30.4% (14/46) patients at the age of <25 years old
and 35.2% (50/142) of patients with CD4 cell count <200
cells/μl were developed anemia. There was a significant
association between anemia with CD4 cell count and
TB before HAART initiation. HIV patients with CD4
cell count <200 cells/μl before HAART initiation had
higher prevalence of anemia (35.2%, P =0.001). Similarly7 (2 )%
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Figure 1 Severity of anemia among HIV/AIDS patients at the Universi
the severity of anemia was higher before HAART initiation among HIV posiabout 53.3% (P =0.002) patients with TB had developed
anemia before HAART initiation. However, there was
no association of anemia with sex, age, and WHO clinical
stage (Table 3).
From anemic patients after HAART initiation, about
7.6% (10/131) were males and 13.8% (30/118) were fe-
males. Similarly 12.3% (14/146) patients at the age of
36–45 years old and 18% (18/100) patients with CD4 cell
count <200 cells/μl were developed anemia. Although,
HIV patients with CD4 cell count <200 cells/μl had
higher prevalence of anemia (18%) after HAART initi-
ation, there was no significance association between
anemia and CD4 cell count (P =0.051). Similarly sex, age
regimen type and WHO clinical stage had no association
with anemia (Table 4).
Discussion
In this study prevalence of anemia was 21.2% and 11.5%
before HAART initiation and after HAART initiation re-
spectively. This indicates that prevalence of anemia was
higher in untreated patients. This is consistent with
study conducted in Minillik II hospital ART clinic, Addis
Ababa Ethiopia 200 (52.6%) and (37.3%) [12], Hawassa
from 2007–2011 (86.5%) and (80.5%) before HAART
initiation and after HAART initiation [13]. This is due
to the fact that HIV disease progression is directly re-
lated to the prevalence and the severity of anemia.
Anemia has been shown to be statically significant pre-
dictor of progression to the AIDS and is independently
associated with an increased risk of death in patient
with HIV [6]. Treatment with HAART suppresses viral
replication and increases CD4 cell count [17]. This in
turn increases immunity and decreases the effect of HIV
on hematopoietic stem cells and different opportunistic
infections [7].40 (11.5%)
15 (4.3%)
24 (6.9%)
emia Mild anemia
nemia
Before
After
ty of Gondar Hospital Northwest Ethiopia. The figure indicates that
tive patients.
Table 3 Anemia and its associated factor before HAART
initiation in HIV patients attending University of Gondar
hospital, North West Ethiopia from 2008-2013
Variables Anemic Non-
anemic
X2 P
value
Sex Male 26
(19.8%)
105 (80.2%) 0.23 0.63
Female 48 (22%) 170 (78%)
Age <25 years 14(30.4%) 32(69.6%) 3.44 0.33
26-35 years 32(20.8%) 122(79.2%)
36-45 years 23(20.2%) 91(79.8%)
>46 years 5(14.3%) 30(85.7%)
Opportunistic
infection
Yes 8(53.3%) 7(46.7%) 9.68 0.002
No 66(19.8%) 268(80.2%)
WHO stage WHO stage I & II 42(30.1%) 184(169.7%) 2.61 0.455
WHO stage III &
IV
32(53.7%) 91(145.7%)
CD4 cells//μl <200 50(35.2%) 92(64.8%) 31.25 0.000
200-350 20(15.5%) 109(84.5%)
>350 4(5.1%) 74(94.9%)
Note: Level of significance (P value) derived from chi square test, Numeric
numbers in bold indicates statistical significant.
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in this study was lower than study done in different coun-
tries, such as Germany from 2001–2002 (61%) [8], India in
2008 (84.6%) [10], Baltimore Maryland (40%) [9], Tanzania
(77.4% [16], Minillik II hospital, Addis Ababa in 2000
(52.6%) [12] and Hawassa from 2007 – 2011(86.5%)
[13]. This discrepancy is due to the difference in study
population, socio demographic characteristics and study
design methods.Table 4 Anemia and its associated factor after HAART
initiation in HIV patients at University of Gondar
hospital, North West Ethiopia from 2008-2013
Variables Anemic Non-anemic X2 P value
Sex Male 10(7.6%) 121(92.4%) 3.028 0.082
Female 30(13.8%) 188(86.2)
Age <25 years 6(13%) 40(87%) 1.336 0.721
26-35 years 18(11.7%) 136(88.3%)
36-45 years 14(12.3%) 100(87.7%)
>46 years 2(5.7%) 33(94.3%)
Regimen type AZT based 24(11.2%) 191(88.8%) 0.049 0.825
Non AZT
based
16(11.9%) 118(88.1%)
Cotrimoxazole Yes 35(11.4%) 271(88.6%) 0.001 0.971
No 5(11.6%) 38(88.4%)
CD4 cells//μl <200 18(18%) 82(82%) 5.953 0.051
200-350 12(8.5%) 130(91.5%)
>350 10(9.3%) 97(90.7%)Prevalence of anemia after HAART initiation (11.5%)
was lower study done in in studies from Minillik II hos-
pital, Addis Ababa 200 (37.3%) [12] and Hawassa from
2007–2011 (80.5%) [13]. This is due to the difference in
the awareness of the patients about HAART was in-
creased and use as recommendation and the time of the
study done.
The prevalence of anemia observed across sex groups
before HAART initiation was 19.8% (26/131) for males
and 22% (48/218) for females similarly after HAART initi-
ation 7.6% (10/131) and 13.8% (30/218) were male and fe-
male patients were anemic respectively. This was slightly
lower than a report from Minillik II hospital ART clinic,
Addis Ababa Ethiopia, 70.25% vs. 29.75% in males and fe-
males before HAART initiation and 69.23% vs. 30.77% in
males and females after HAART initiation respectively
[12]. Prevalence of anemia was decreased after HAART
initiation from 19.8% to 7.6% in males and from 22% to
13.8% in females.
In this study the minimum and maximum CD4 cell
count before HAART initiation was 1 cell/μl and 795
cells/μl and after HAART initiation were 14 cells/μl and
969 cells/μl. Patients with CD4 cell count <200 cells/μl
before HAART initiation was 142 (40.7%) while after
HAART initiation was 100 (28.7%). The risk of having
CD4 cell count <200 cells/μl was increased before HAART
initiation, because before HAART initiation patients have
less immunity towards the HIV and the virus attacks CD4
cells easily.Conclusion
There was a decline in the prevalence of anemia and incre-
ment of mean CD4+ T cell count among HIV infected pa-
tients after HAART initiation. Before HAART initiation,
HIV patients have significantly higher prevalence of
anemia than those after HAART initiation. The prevalence
of anemia was significantly higher in patients with CD4
cell count <200 cell/μl. There was a significant association
between prevalence of anemia with CD4 cell count and
opportunistic infections before HAART initiation. But
there was no association of prevalence of anemia with sex,
age, regimen type and WHO clinical stage. Based on the
present finding, HIV patients are recommended to check
up their CD4 cell counts regularly and start HAART when
it is appropriate in order to decrease the prevalence of
anemia.
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